Melatonin as biological response modifier in cancer patients
- PMID: 9615811
Melatonin as biological response modifier in cancer patients
Abstract
The neuroendocrine system modulates the immune response through neuropeptides and neurohormones, findings which point to the existence of a neuro-endocrine-immune system regulatory axis. At the same time, there is growing evidence that the pineal gland has anti-neoplastic properties, which include the action of its principal hormone, melatonin (MLT), on the immune system through the release of cytokines by activated T-cells and monocytes. The present study was carried out on 31 patients (19 males and 12 females, age range 46-73 years) with advanced solid tumors (7 gastric, 9 enteric, 8 renal, 5 bladder, 2 prostate) who either failed to respond to chemotherapy and radiotherapy or showed insignificant responses and were therefore shifted to MLT therapy (10 mg/die orally for 3 months). We obtained blood samples just before the start of MLT administration and after 30 days of therapy. Plasma was collected in EDTA tubes on ice, immediately centrifuged at 4 degrees C and stored frozen at -80 degrees C; samples were measured by immunoradiometric assays (Medgenix-Fleurus, Belgium) for tumor necrosis factor alpha (TNF), interleukin-1, 2 and 6 (IL-1, IL-2, IL-6) and interferon gamma (IFN). We used Student's paired t-test to compare each patient's cytokine circulating levels before and after MLT administration and found a significant differences (p < 0.05). After 3 months of therapy, none of our patients displayed adverse reactions to MLT or had to discontinue treatment. Nineteen patients (61%) showed disease progression. The other 12 (39%), however, achieved disease stabilization with no further growth of either the primary tumor or of secondaries; moreover, they experienced an improvement in their general well-being, in terms of Tchekmedyian's criteria, associated with a significative decrease of IL-6 circulating levels. These findings are consistent with the hypothesis that MLT modulates immune function in cancer patients by activating the cytokine system which exerts growth-inhibitory properties over a wide range of tumor cell types. Furthermore, by stimulating the cytotoxic activity of macrophages and monocytes, MLT plays a critical role in host defence against the progression of neoplasia.
Similar articles
-
Effects of melatonin administration on cytokine production in patients with advanced solid tumors.Oncol Rep. 1995 Jan;2(1):45-7. Oncol Rep. 1995. PMID: 21597686
-
Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.J Biol Regul Homeost Agents. 1994 Oct-Dec;8(4):126-9. J Biol Regul Homeost Agents. 1994. PMID: 7660855
-
A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.Anticancer Res. 2000 May-Jun;20(3B):2103-5. Anticancer Res. 2000. PMID: 10928160 Clinical Trial.
-
Is there a role for melatonin in supportive care?Support Care Cancer. 2002 Mar;10(2):110-6. doi: 10.1007/s005200100281. Epub 2001 Nov 13. Support Care Cancer. 2002. PMID: 11862501 Review.
-
Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.Anticancer Res. 2006 Mar-Apr;26(2A):1113-34. Anticancer Res. 2006. PMID: 16619514 Review.
Cited by
-
Effects of melatonin in reducing the toxic effects of doxorubicin.Mol Cell Biochem. 2006 Jun;286(1-2):11-5. doi: 10.1007/s11010-005-9003-8. Epub 2006 Apr 20. Mol Cell Biochem. 2006. PMID: 16652224
-
Antagonistic effect of luzindole in mice treated with melatonin during the infection with the venezuelan equine encephalomyelitis virus.Neurochem Res. 2009 Feb;34(2):268-73. doi: 10.1007/s11064-008-9766-x. Epub 2008 Jul 2. Neurochem Res. 2009. PMID: 18594966
-
Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application.Aging Dis. 2023 Jun 1;14(3):840-857. doi: 10.14336/AD.2022.1010. Aging Dis. 2023. PMID: 37191417 Free PMC article. Review.
-
Melatonin, an Antitumor Necrosis Factor Therapy.J Pineal Res. 2025 Jan;77(1):e70025. doi: 10.1111/jpi.70025. J Pineal Res. 2025. PMID: 39740227 Free PMC article. Review.
-
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review.Curr Oncol. 2024 Apr 3;31(4):1994-2023. doi: 10.3390/curroncol31040149. Curr Oncol. 2024. PMID: 38668052 Free PMC article. Review.